Improved osteosarcoma survival with addition of mifamurtide to conventional chemotherapy – Observational prospective single institution analysis
Purpose: Conventional osteosarcoma is an orphan disease. Current treatment approaches include combining a three drug chemotherapy schedule and surgery. The 3- and 5-year event-free survival (EFS) in localized disease is roughly 65 and 60%, respectively. The registration study of mifamurtide reported...
Main Authors: | Peter Múdry, Michal Kýr, Ondřej Rohleder, Michal Mahdal, Iva Staniczková Zambo, Marta Ježová, Tomáš Tomáš, Jaroslav Štěrba |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-06-01
|
Series: | Journal of Bone Oncology |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2212137421000166 |
Similar Items
-
Review of mifamurtide in the treatment of patients with osteosarcoma
by: Leo Kager, et al.
Published: (2010-06-01) -
Chemotherapy in the management of periosteal osteosarcoma: A narrative review
by: Tarek Assi, et al.
Published: (2021-10-01) -
Mifamurtide for the treatment of osteosarcoma: a single technology appraisal
by: A Pandor, et al.
Published: (2009-10-01) -
Suboptimal chemotherapy is an adverse prognostic factor in osteosarcoma
by: Yong Bicheng, et al.
Published: (2012-09-01) -
Conventional osteosarcoma of the mandible: Report of a rare case
by: Hassan Mirmohammad Sadeghi, et al.
Published: (2021-09-01)